Paskaitos medžiaga (video)

Paskaitos medžiaga (video)

PASKAITOS VIDEO BLOCK

Literatūros sąrašas

  1.  Compston A, Coles A. Multiple sclerosis. Lancet. 2008; Oct 25;372(9648):1502-17.
  2.  Ghezzi, A, Zaffaroni, M. Female-specific issues in multiple sclerosis. Expert review of neurotherapeutic. 2008; 8 (6), 969-977.
  3.  Tremlett H et al. New perspectives in the natural history of multiple sclerosis Neurology 2010;74:2004-15.
  4. Sorensen PS. The changing epidemiology in MS. 2008.
  5. Kizlaitiene R, Budrys V et al.  Prevallence of multiple sclerosis in Lithuania and the in fluence of immunomodulating treatment on annual hospitalization, ECTRIMS, Montreal, Canada, September 17- 20, Multiple Sclerosis 2008;
  6. Greer JM, McCombe P. Role of gender in multiple sclerosis: clinical effects and potential molecular mechanisms. J Neuroimmunol 2011;234:7-18.
  7. .Oksenberg RJ, Baranzini ES. Multiple sclerosis genetics- is the glass half full, or half empty?  Nat Rev Neurol 2010;6:429-437.
  8.   Milo R, Kahana E. Multiple sclerosis: geoepidemiology, genetics and the environment. Autoimmun Rev 2010;9:387-394.
  9. Harirchian MH et al. Worldwide prevalence of familial multiple sclerosis: a systematic review and meta-analysis.Mult Scler Relat Disord; 20 : 43-47.
  10. Ascherio A, Munger K. Enviromental risk factors for multiple sclerosis. Part I:role of infection.
     Part II: Noninfectious factors. Ann Neurol 2007;61:288-299
  11. ¹Ascherio A, Munger KL, Simon Claire K. Vitamin D and multiple sclerosis. Lancet Neurol 2010;9:599-612.
  12. Montgomery SM, Bahmanyar S, Hillert J, EkbomA, Olsson T. Maternal smoking during pregnancy and multiple sclerosis amongst offspring.
    Eur J Neurol 2008;15:1395-1399.
  13. Hedstrom AK, Baarnhielm M, Olsson T, Alfredsson L. Tobacco smoking, but not Swedish snuff use, increases the risk of multiple sclerosis. Neurology 2009;73:696-701.
  14. Giovannoni G. Epstein-Barr virus and MS. Int MS J 2011;17:44-49.
  15.  Ascherio A, Munger KL. Environmental Risk Factors for Multiple Sclerosis. Part I: The Role of Infection. Ann Neurol 2007;61:288-299.
  16.  Noseworthy JH et al. N Engl J Med 2000;343:938–52; 2. Runmarker B, Andersen O. Brain 1993;116:117–34.
  17. Rogers and Oanegyres. J Clin Neurosci. 2007;14:919; Tsang and Macdonell. Aust Fam Physician. 2011;40:948.
  18. Chen L et al. Curr Opin Ophthalmol. 2005;16:315-320; 2. Della Salla S et al. J Neurol Neurosurg Psychiatry. 1987;50:840-846;
  19. Danesh-Sani SA et al. J Oral Maxillofac Surg. 2013;71:290-294; 4. Heesen C et al. Mult Scler. 2008;14:988-991
  20. Sakai RE et al. J Neuroophthalmol. 2011;31:362-373
  21. Hadjimichael O et al. Health Qual Life Outcomes. 2008:6:100;
  22.  Krupp LB et al. Arch Neurol. 1988; 45:435-437;
  23.  Fisk JD et al. Can J Neurol Sci. 1994;21:9-14; 
  24. Penner IK et al. Mult Scler. 2009;15:1509-1517;
  25. Amato MP et al. J Neurol Sci. 2006;245:41-46;
  26. Jongen PJ et al. Minerva Med. 2012;103:73-96;
  27. Flensner G et al. BMC Public Health. 2013;13:224; 8. Rao SM et al. Neurology. 1991;41:692-696
  28. Schumacher et al. And McDonald et al. (2001).
  29. Polman CH, Reingold CS, Banwell B, Clanet M, Cohen AJ, Filippi M et al. Diagnostic Criteria for Multiple Sclerosis: 2010 revisions ti the McDonald Criteria. Ann Neurol 2011;69:292-302.
  30. Broman T, et al. Acta Neurologica Scandinavica 1965;2:543–548; Thompson AJ, et al. Lancet Neurology 2017;17:162-173.
  31. Siritho S, Freedman MS. The prognostic significance of cerebrospinal fluid in multiple sclerosis. J Neurol Sci 2009;279:21-25.
  32. Idiman E, Ozakbas S, Dogan Y, Kosehasanogullari G. The significance of oligoclonical bands in multiple sclerosis: relevance of demographic and clinical features, and immunogenetic backgrounds. J Neuroimmunol 2009; 212:121-124.
  33. Schwenkenbecher P, Sarikidi A, Wurster U, et al. McDonald criteria 2010 and 2005 compared: Persistence of high oligoclonal band prevalence despite almost doubled diagnostic sensitivity. Int. J. Mol. Sci. 2016;17(9).
  34. ADEM, acute disseminated encephalomyelitis; CADASIL, human T-cell lymphotropic virus; CNS, central nervous system; HIV, human immunodeficiency virus;HTLV, human T-cell lymphotropic virus; MS, multiple sclerosis; NMO, neuromyelitis optica; PML, progressive multifocal leukoencephaolopathy.
    Eckstein C, et al. J Neurol 2012;259:801–16.
  35. Kieseier BC, Stuve O. Nat Rev Neurol 2011;7:255–62;
  36.  Ziemssen T et al. J Neurol 2016;263:1053–65.
  37.  Sormani MP, De Stefano N. Nat Rev Neurol 2013;9:504–12.
  38. Bevan CJ, Cree BA. JAMA 2014;71:269–70.
  39.  Sormani MP et al. Mult Scler 2011;17:541–9.
  40.  Kappos L et al. Mult Scler 2016;22:1297–305. 
  41. Havrdova E et al. Lancet Neurol 2009;8:254‒6.
  42. Tintoré M. J Neurol Sci 2009;277:S9–S11.
  43. Jacobs LD et al. N Engl J Med 2000.
  44. 343:898–904; Comi G et al. Lancet 2001.
  45. 357:1576–82; Kappos L et al. Neurology 2006
  46. Giovannoni G et al. Mult Scler Relat Disord 2015;4:329–33